LEXAPRO
Clinical safety rating
cautionComprehensive clinical and safety monograph for LEXAPRO (LEXAPRO).
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram. |
| Excretion | Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%. |
| Half-life | 27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses. |
| Protein binding | Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | 12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity. |
| Bioavailability | Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption. |
| Onset of Action | Oral: 1-2 weeks for initial therapeutic effect; full effect may require 4-6 weeks. No IV formulation. |
| Duration of Action | 24 hours with once-daily dosing; sustained receptor occupancy due to long half-life; washout period >2 weeks recommended before switching MAOIs. |
| Molecular Weight | 324.39 |
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (CrCl <20 mL/min). |
| Liver impairment | For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data. |
| Pediatric use | Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved. |
| Geriatric use | Initial 5 mg orally once daily; maximum 10 mg once daily. |
| 1st trimester | Epidemiological studies have not established a consistent causal association between first-trimester exposure and major congenital malformations. However, some studies suggest a small increased risk of cardiovascular malformations, particularly septal defects, with an absolute risk increase <1%. Paroxetine is the only SSRI with stronger evidence of first-trimester risk. |
| 2nd trimester | No specific increased risk of major malformations has been identified with second-trimester exposure. Fetal growth and development should be monitored. |
| 3rd trimester | Late-third-trimester exposure may be associated with persistent pulmonary hypertension of the newborn (PPHN), although absolute risk is low (approximately 3-6 per 1000 live births). Neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) occurs in up to 30% of exposed neonates, typically self-limiting. |
Clinical note
Comprehensive clinical and safety monograph for LEXAPRO (LEXAPRO).
| Placental transfer | Escitalopram crosses the placenta, with a cord-to-maternal plasma ratio of approximately 0.5-0.6, indicating significant but incomplete transfer. |
| Breastfeeding | Escitalopram is excreted into breast milk in low concentrations. Infant serum levels are typically undetectable or subtherapeutic. No adverse effects have been consistently reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding. Monitor infant for drowsiness, poor feeding, or weight gain. |
| Lactation Rating | L2 (Hale's Lactation Risk Category: Safer) |
| Teratogenic Risk | First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties. |
| Fetal Monitoring | Monitor maternal mental health status, and watch for signs of serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability). For the fetus, monitor growth and well-being with serial ultrasound assessments, particularly in the third trimester. Neonates exposed in utero should be observed for adaptation syndrome symptoms and PPHN (pulse oximetry screening). |
| Fertility Effects | Animal studies show no impairment of fertility; however, human data are limited. SSRIs may affect sperm quality and libido. Escitalopram can cause sexual dysfunction (delayed ejaculation, anorgasmia) which may impact fertility indirectly. No specific adverse effects on female fertility have been reported. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuationConcurrent use with pimozideKnown hypersensitivity to escitalopram or any excipientConcurrent use with linezolid or intravenous methylene blue due to risk of serotonin syndrome
| Precautions | Suicidality risk in young adults, Serotonin syndrome, QT prolongation, Hyponatremia, Bleeding risk, Activation of mania/hypomania, Seizure risk, Abrupt discontinuation syndrome |
| Food/Dietary | Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food. |
| Clinical Pearls | LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients. |
| Patient Advice | Take LEXAPRO once daily, either in the morning or evening, consistently with or without food. · Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms. · Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners. · Avoid alcohol and grapefruit juice as they may increase side effects. · Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting). · It may take several weeks to feel the full benefit; continue taking as prescribed. · Monitor for worsening depression or anxiety, especially during the first few months of treatment. · If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications). |
Loading safety data…